adenosine 30mg/10ml solution for infusion vials
wockhardt uk ltd - adenosine - solution for infusion - 3mg/1ml
adenosine injection, solution
akorn - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - adenosine 3 mg in 1 ml - adenosine injection is indicated for the following. conversion to sinus rhythm of paroxysmal supraventricular tachycardia (psvt), including that associated with accessory bypass tracts (wolff-parkinson-white syndrome). when clinically advisable, appropriate vagal maneuvers (e.g., valsalva maneuver), should be attempted prior to adenosine administration. it is important to be sure the adenosine solution actually reaches the systemic circulation (see dosage and administration ). adenosine does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. in the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine administration. adenosine injection is contraindicated in: - second- or third-degree a-v block (except in patients with a functioning artificial pacemaker). - sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a functioning artificial pacemaker). - known hypersensitivity to adenosine.
adenosine injection, usp
cardinal health - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - adenosine 3 mg in 1 ml - adenosine injection is indicated for the following. conversion to sinus rhythm of paroxysmal supraventricular tachycardia (psvt), including that associated with accessory bypass tracts (wolff-parkinson-white syndrome). when clinically advisable, appropriate vagal maneuvers (e.g., valsalva maneuver), should be attempted prior to adenosine administration. it is important to be sure the adenosine solution actually reaches the systemic circulation (see dosage and administration ). adenosine does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. in the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine administration. adenosine injection is contraindicated in:
adenosine injection, solution
general injectables & vaccines, inc - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - adenosine 3 mg in 1 ml - adenosine injection is indicated for the following. conversion to sinus rhythm of paroxysmal supraventricular tachycardia (psvt), including that associated with accessory bypass tracts (wolff-parkinson-white syndrome). when clinically advisable, appropriate vagal maneuvers (e.g., valsalva maneuver), should be attempted prior to adenosine administration. it is important to be sure the adenosine solution actually reaches the systemic circulation (see dosage and administration ). adenosine does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. in the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine administration. adenosine injection is contraindicated in: - second- or third-degree a-v block (except in patients with a functioning artificial pacemaker). - sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a functioning art
adenosine injection
gland pharma limited - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - adenosine 3 mg in 1 ml - adenosine injection, usp is indicated for the following: conversion to sinus rhythm of paroxysmal supraventricular tachycardia (psvt), including that associated with accessory bypass tracts (wolff-parkinson-white syndrome). when clinically advisable, appropriate vagal maneuvers (e.g., valsalva maneuver), should be attempted prior to adenosine administration. it is important to be sure the adenosine solution actually reaches the systemic circulation (see dosage and administration ). adenosine does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. in the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine administration. adenosine injection is contraindicated in: 1. second- or third-degree a-v block (except in patients with a functioning artificial pacemaker). 2. sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patien
adenosine injection, solution
akorn - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - adenosine injection, usp is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. adenosine injection is contraindicated in patients with: - second- or third-degree av block (except in patients with a functioning artificial pacemaker) [see warnings and precautions (5.2)] - sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a functioning artificial pacemaker) [see warnings and precautions (5.2)] - known or suspected bronchoconstrictive or bronchospastic lung disease (e.g., asthma) [see warnings and precautions (5.3)] - known hypersensitivity to adenosine injection [see warnings and precautions (5.7)] pregnancy category c . animal reproduction studies have not been conducted with adenosine; nor have studies been performed in pregnant women. because it is not known whether adenosine can cause fetal harm when administered to pregnant women, adenosine should be used during pregnancy only if clearly needed. it is not known whether adenosine is excreted in human milk. because many drugs are excreted in human milk and because of the potential for serious adverse reactions from adenosine in nursing infants, the decision to interrupt nursing after administration of adenosine or not to administer adenosine, should take into account the importance of the drug to the mother. the safety and effectiveness of adenosine in patients less than 18 years of age have not been established. clinical studies with adenosine injection did not include sufficient numbers of subjects aged younger than 65 years to determine whether they respond differently. other reported experience has not revealed clinically relevant differences of the response of elderly in comparison to younger patients.
adenocor
sanofi malta limited level2, fort business centre, mriehel bypass, birkirkara, malta - adenosine - solution for injection - adenosine 3 mg/ml - cardiac therapy
adenosine solution
gland pharma limited - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - intravenous adenosine injection is indicated for the following. conversion to sinus rhythm of paroxysmal supraventricular tachycardia (psvt), including that associated with accessory bypass tracts (wolff-parkinson-white syndrome). when clinically advisable, appropriate vagal maneuvers (e.g., valsalva maneuver), should be attempted prior to adenosine injection administration. it is important to be sure the adenosine injection solution actually reaches the systemic circulation (see dosage and administration). adenosine injection does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. in the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosineinjection administration. intravenous adenosine injection is contraindicated in: 1. second- or third-degree a-v block (except in patients with a functioning artificial pacemaker). 2. sinus node disease, such as sick sin
adenoscan for iv infusion 3 mg/ml
sanofi-aventis singapore pte. ltd. - adenosine - injection - 3 mg/ml
adenocard- adenosine solution
astellas pharma us, inc. - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - adenosine 3 mg in 1 ml - intravenous adenocard (adenosine injection) is indicated for the following. conversion to sinus rhythm of paroxysmal supraventricular tachycardia (psvt), including that associated with accessory bypass tracts (wolff-parkinson-white syndrome). when clinically advisable, appropriate vagal maneuvers (e.g., valsalva maneuver), should be attempted prior to adenocard administration. it is important to be sure the adenocard solution actually reaches the systemic circulation (see dosage and administration). adenocard does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. in the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenocard administration. intravenous adenocard (adenosine injection) is contraindicated in: